This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: Good morning and welcome to Mulek Science's second quarter 2024 conference call. My name is Stefania Shepkov of ICR Strategic Communications and Advisory. During this conference call, all participant lines will be muted until after the management's remarks when there will be a question and answer session. Please also note that today's session is being recorded. Today, Mulek announced its second quarter fiscal year 2024 business highlights. The document is now available on the company's investor relations website at ir.mulekscience.com. This morning, you will be hearing from Gaston Palladini, Chief Executive Officer and co-founder of Mulek Science, together with Jose Lopez-Lacube, Chief Financial Officer, and Amit Dhingra, Chief Science Officer. Hank Hugenkamp, Chief Product Officer, will also be joining the subsequent question and answer session to be held immediately after the business update remarks. In today's call, we will be referring to a presentation that is available on the company's investor relations website. Moving on to slide two. This conference call is mainly for informational purposes. And during this call, the company will be making forward-looking statements regarding future events and results, which are not historical facts and include, but are not limited to, statements about the company's beliefs and expectations. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks are included in the company's annual report on Form 20F filed with the SEC, also available on the company's investor relations website. Now, moving to slide three, I would like to turn the call over to MULEC's CEO, Gaston. Please go ahead.
spk04: Thank you, Stephanie, and good morning, everyone. I am glad to present to our attending audience our last business update. As we have been doing over the last couple of conferences, today's agenda will address three different topics. First, I will give a quick review of Bullock's strategy pillars for value creation. Second, Amit will walk you through our last scientific and operational developments. And finally, Jose will present our financial highlights from Q2. Here, I would like to take the opportunity to introduce our framework for value creation. Let's move now to a slide five. This framework not only organize, but also illustrate the way in which we are creating value for all of our stakeholders. we have refined our current business strategy into four foundational pillars. Allow me to provide a more detailed overview. Number one, product development. This pillar includes research and development, product creation and improvement, and associated processes to ensure the highest standard of food and environmental safety and quality. Our primary focus is on developing disruptive solutions using innovative technology for the food industry. Number two, patent portfolio. Our strategy objective is to evolve into an IP powerhouse. R&D is feeding our portfolio and will incorporate a wide spectrum of patents that covers methods, processes, and applications. We continuously screen the market to identify the most valuable geographic areas for our IP efforts, ensuring our assets align with market demands. Third, regulatory pathway. We possess deep knowledge and expertise in navigating regulatory approval processes, such as those with the FDA and the USDA in the United States, among, of course, other territories as well. Our objective is to navigate the regulatory landscape swiftly and efficiently, maintaining compliance while minimizing time to market. Number four, strategic alliances. Building a strategic partnership with leading industry players is crucial to accelerate and complement our business. These alliances are pivotal for the exchange of technology, expertise, and industrial processes, ultimately enhancing our competitiveness in the market. This framework is our roadmap for planning and execution, providing a comprehensive and focused approach to achieving our objectives. Before I hand over to Amit to discuss operational progress, let's move to slide number six, where we will examine the status of our pipeline. As illustrated, most of the projects maintain their status with notable internal progress in GLASSO and SOIL-1. However, I would like to highlight the exceptional advancement in year one project, specifically in progression in product development. Now I leave you with Amit Dhingra, Murex Chief Science Officer, who will provide a true overview of our technical and operational advancement.
spk00: Thank you, Gaston. Greetings to all of you. We will move now to slide eight. I'm excited to present our technical and operational milestones. We continue to make progress on our PiggySwipe platform. We are getting ready to harvest the fourth generation or T4 seeds in April this year. In the meantime, our team performed analysis on the stability of the porcine myoglobin gene, The gene is no longer segregating, which means that it is genetically stable in the selected lines. I am also excited to share that the integration of the bovine myoglobin gene has now been confirmed in several first generation T1 or second generation T2 seeds, indicating that the myoglobin gene is being stably integrated across the generations. Moving now to slide nine, I'm excited to provide an update on Mulex prototyping division using our novel yeast platform. Our objective is to identify high value applications for a yeast strain that's new to the food industry. This platform not only finds value for a novel microorganism, but also paves the way for future target molecules to be economically viable by distributing overhead costs across multiple products. Specifically, we have found traits in this yeast strain which allowed us to adapt standard processing techniques to produce an iron supplement that's novel to the market. Preliminary data is promising, indicating that this supplement could approach the efficacy and cost efficiency of traditional animal-derived nutritional supplements, particularly in terms of iron absorption. A regulatory pre-submission meeting was held with the FDA. We feel encouraged to continue our efforts. On to slide 10. Our immediate focus is on scaling our production. We plan to produce successive batches at the pilot level, ultimately increasing the capacity to 1,000 liter batches. These larger batches will allow us to create standardized prototypes, which will be thoroughly characterized. The insights gained from the characterization will be instrumental in finalizing our safety dossier and more precise cost computations. Additionally, we aim to leverage any surplus material by offering our samples to potential partners and stakeholders. Now, I will pass on the presentation to my colleague and our CFO, Jose. Thank you.
spk03: Thank you, Amit. And good morning to everyone. It is a pleasure to be providing this business update of MULEC for the second quarter of fiscal year 2024. Today, I would like to take some time to review our latest highlights with regards to revenues, expenses, and cash utilization. Please keep in mind that all figures mentioned today are in U.S. dollars and audited and based or derived from IFRS unless otherwise stated. Let's move on now to slide 12. Before we deep dive into the numbers, I would like to point out that in this quarter financials, we are also introducing normalized figures that exclude the effect of the application of IAS 29 accounting in our Argentine subsidiary, which has the Argentine peso as functional currency. For those of you not familiar with IAS 29, it is an accounting adjustment applied in hyperinflationary economies, which utilizes the end of period exchange rate to convert revenues and expenses into US dollar. For this period, given that the Argentine peso was evaluated 125% in the last 15 days of the quarter, it affects our as reported numbers in a way that we understand does not reflect the evolution of the underlying business. Mulek subsidiary is located in Argentina, but the business mostly operates in U.S. dollars, given its product export nature and its raw material procurement needs. In this sense, we believe that normalized revenues and COGS, including the IAS 29 effect, better reflect the reality of the business. Moving on now to the performance of the operations, during the second quarter, we continued originating soybean efficiently and delivering a sustained coverage of the existing commercial geographic footprint. Normalized revenues and other income excluding IIS29 effect were around $1.7 million, generally in line versus last quarter with a slight decrease in volume. On the other hand, as reported revenues and other income were approximately $0.5 million. As mentioned before, this decline is mainly due to the application of IIS 29 accounting. In terms of COGS, excluding IIS 29 figures decreased versus last quarter, mainly due to lower value of inventories of our subsidiary in Argentina as a result of the devaluation of the local currency at the end of the period. SG&A expenses have remained generally in line with our historical track record with no significant changes, continuing an efficient trend of low expenditure while supporting the company's progress. In particular, R&D expenses increased slightly quarter over quarter, but partially offset by lower admin and marketing expenses. Cash utilization was approximately $4 million which remains in line with our historical track record of controlled cash expenses. And it also includes around $2.7 million in non-recurring payments associated with transaction expenses. Finally, during December, 2023, Mulek raised an additional $1 million through the issuance of a convertible note with farmers. The terms and conditions were the same as the previous capital raise, closed with strategic investors Grupo Insud and Bioceres Crop Solutions for $30 million. We are very pleased with the incorporation of these strategic investors, most recently farmers, who will be instrumental not only in our funding health, but also contribute to support MULEC product growth and commercialization in the near future. I will now turn things over to Stephanie for the Q&A portion of our call. Thank you.
spk01: Thank you, Jose. At this time, our management will be taking questions. You may submit questions through the chat box, submitting your name and firm in the chat or by using the hand raising function. Please be advised that we will ask you to unmute your line to ask your question. We ask those who would like to participate in the Q&A, if your name and firm is not indicated below your image, please right click your image, click rename, and enter your firm and full name before asking a question. Again, you may submit questions through the chat box or use the hand raising function. Thank you. Before we take questions from the live queue, we have received a few questions via email. So first question for management, in the business update you highlighted Soy One, 10 T3 events and that the T4 seeds will be harvested in April. What do you expect or hope to see in the T4 seeds and what is next for your soy product?
spk04: Well, thank you, Stephanie, and thank you for the question. Good morning to everyone. Well, I'm very happy to... to have SOI1 on track. So I will leave the floor to Amit Dhingra to fully explain what is next, our following steps. So moving from T1, sorry, to T4 onwards. So Amit, could you please explain for the details of this project?
spk00: Certainly. Thank you, Gaston. Good morning, everyone. So there are two parts to this as we are moving towards T4 seeds. There is the scientific part that we continue to perform quality control to look at the expression levels as well as the integration of the porcine myoglobin on one side. And secondly, we will have enough seed this time now. to start utilizing it for downstream. And we will be passing on a lot of that seed material to my colleague, Hank, who's the chief product officer. And he can elaborate on that, how will the seed be utilized in various applications. Over to you, Hank. Thank you.
spk05: Thank you, Amit. Good morning, everybody. So of course, I'd like to for that. I'm very excited that we're getting more seeds to start the actual development processes on applications. but also sparing some seed to start sending to our most important pre-commercial customers. So first of all, or second of all, I'd also like to say is that the efforts led by iMeet to scale up the seeds will also yield in growing amounts of samples that are available for our customers so that we can scale along with them. So this means that the sampling process has begun and we're very confident that we can meet the needs of customers
spk01: Thank you for your answer. The second question that we have through email, it says, in this quarter's presentation, you highlighted your yeast product. Yeah, one. Can you help us better understand your next steps there? What final steps are needed to enter commercialization and help us understand that opportunity? What kind of customers or market size are you seeing?
spk04: Well, thank you, Stephanie, and thank you for the question. So continue talking about our pipeline status and the next step. So I'm happy to say that Henk Hueckheim is leading this specific project in Europe, multibasic in Europe. So Henk, will you please explain the... the details of year one and also highlighting, of course, the market opportunity that is very exciting. So, Hen, go ahead.
spk05: Thank you, Gaston. Also, thanks for the question. Basically, our immediate priority is to scale up our process, which is planned in the coming quarter. And the scaling up will yield a characterized prototype. So this is a prototype that can be used for the further refinement of our safety dossier, a further understanding of the characteristics, and any excess samples can be then shared with our potential customers in the pre-commercial processes. Parallelly, we're having continuous regulatory refinements and consultations, as Amit already mentioned in the presentation. This is really important because everything that we try and do is always try with full regulatory compliance in mind or finding the path of least regulatory resistance. In terms of the markets, our initial target is the iron supplementation, but also fortification markets, which has a rough size, about $1 billion. US dollars. Of course, this market access is something that is really important to us. So it's also worth noting that our strategic partner, Grupo Ensud, who is not only providing the industrial capacities to scale up and to produce fully compliant qualities, they also have access to the market through their portfolio companies. So this is actually a fairly closed loop in terms of from beginning to end, from product idea to production to potential market access. And that's what we're really later to focus on right now to close the gap.
spk01: Great. Thank you. So we are going to be taking questions from the live queue now. I see a question from Thomas McGovern of Maxim Group. At this time, I'm going to give you permission to speak live and ask your questions live on the call. If you can unmute your line, you may ask your question live, Brian.
spk02: All right, guys, thanks for taking my question. So yeah, first question is related to the gold food trade show and those associated 50 qualified leads that you mentioned in the press release. So I was wondering if you could just give a little bit more detail on that, you know, kind of where those qualified leads are at. And then maybe if you could talk a little bit about which ingredient products specifically those leads are interested in purchasing. Thanks.
spk04: Sure. Well, thank you, Thomas, for the question. I will take the second one, and Ken will elaborate on the whole food trade show because he attended the show personally in Dubai. Well, the ingredient products are soy-based meat analogs, mostly. They have been developing new techs and improvements of our current products. So mostly we use goal-foot ratio to present these innovative and new samples. But nobody better than Hank to fully explain the show and to give you some insight and good info about what happened there in Dubai. Hank?
spk05: Thank you. So also thanks for the question. In this case, the Gulf food is one of the leading shows for people all over the world to aggregate. Also, it's a really important show where ingredients are showed not only for, let's say, niche applications, but for the large market, in this case, for meat replacement. And the meat replacement market is not in terms of plant-based, for the plant-based movement, but it's basically the huge market to target to make meat affordable. And that's where currently our meat replacers are selling into the market, into, I believe, currently 11 countries worldwide. um and this this show is where where people aggregate uh so when we have an innovation or at least a an iterative improvements all the way up to an innovation this is a show where you show where you demonstrate this in person you talk to customers live you get live feedback you start to talk to to them what their problems are in terms of either from pricing all the way to texture to to functional applications and here's where you get yeah the live feedback is very valuable in that sense. Also, it's the best place to find new qualified leads in terms of new markets, which we haven't accessed before. And it's not only about showing the commodities that we have currently in the market, but also our path to specialties, which we're currently developing, to have a real-time sense of how it's being received by these potential new markets that we're trying to access.
spk02: I appreciate your response. Yeah, so my second question relates just kind of more generally to the commercialization of several of your planned products. So in the past, you guys have discussed plans to kind of start to ramp up or fortify your sales and marketing efforts ahead of these commercial launches so maybe if you can just you know review that kind of give any updates on that front and just you know just high level kind of what your plans are for expanding your sales and marketing teams appreciate it guys sure good question thomas uh well this is a b2b uh business uh and they're mostly food um
spk04: and dietary supplement business. So that's implied to deliver samples. That's the key to capturing new customers and to engage potential clients. Having said that, what we are doing is co-working with the R&D departments of these potential customers. I can't reveal the names yet of most of them, but these things take time. So that's what we are doing as we speak. Co-working with them, delivering samples, preparing more samples, and characterization of information of the specific ingredients. and deliver that samples to customers. In parallel, we work specifically in commercial terms, in master supplies agreements, in MTAs, in material transfer agreements. So that's how the plan goes. And that's what we are doing as we speak, as I said. The idea is to strengthen the commercial and sales team, since you said, as you said, you are getting closer to commercialization. So that will be my short answer. I don't know, Jose, if you want to expand on that.
spk03: No, sure. Thank you. Tom, what I would add here is that within the current team, there is a huge expertise in terms of the ingredient business and market. And we have that, you know, in Hank's shoulders and we have other people in the team with a lot of years and seasoned professionals in the ingredient business. So we believe we are having very interesting conversations and in the way in the food business. As we get maybe closer to the commercialization of Glasso, and that would be, remember, beginning of 2025, yes, we might have some incorporations to support that expansion in terms of the relationship specifically attached to the Glasso product. But again, I would reinforce and highlight the great knowledge in terms of commerce that will be later this year strengthened with people more focused on the glass of evidence.
spk02: Understood. I appreciate you guys taking the time to answer my questions.
spk01: Thank you. As a reminder, you can ask a question through the chat box or by using the hand raising function. We have one other question that is in through our email. This is for the management. What is the market not understanding adequately about your business?
spk04: Well, thank you, Stephanie. Thank you for the question. I think it's a good one. I will take it, and probably my partners here will compliment on that. I will say that there is three facts to highlight. The first one is the huge term on some market opportunity ahead. We're talking about more than $8 billion term market, around $40 billion term market. And this is, of course, as I've said, considering food, meat applications, and not only just the vegan or alternative protein niche. The opportunity is huge. And also consider, of course, the sustainable trend. Second fact, the extraordinary yield in soy that we got with the Vicky Soy platform, 26.6% of porcine protein over total soluble protein is a lot, is huge. breakthroughs, no brainer. So we patented and the product is moving forward as Amit described it before. And third, lastly, the third fact would be that this team that we are representing the team here, but there is a great team of PhDs and food technologies and professionals in Mulek is delivering milestone I'm getting this product pipeline closer to commercialization. So I will summarize these three facts to answer the question. Of course, there are more, but these are the most important ones. I don't know if my partners here want to compliment on that, but that would be my short answer.
spk03: Well, I would add a ton on top of that, that in the last couple of months, I would say in the last year, year and a half, this company has been delivering results that de-risk the go-to-market strategy. And by delivering on the execution front, we are getting closer and closer to the different stages of commercialization. First, the revenue that we're generating. Second, it will be a glass, as we mentioned before, beginning of 2025. And then the other products related to the molecular farming platform. Having said that, the milestone that we have delivered in terms of science with extraordinary yields in terms of animal protein present in the plants, the progress on the regulatory front, the progress on the IP front, that all encompasses a good execution and the risks that go to market. So we believe that that has a lot of intrinsic value. And going back to your question, we believe that probably the market is not fully understanding the value of that.
spk01: Thank you, management. I would like to conclude today's call as there are no further questions at this time. And I will hand the call back to Mulek's CEO, Gaston, for a few closing remarks.
spk04: Okay, yes. Okay, if there's no further questions, I want to thank you all for joining us today, this conference call. We at Mule continue to work hard on all avenues, and there's a lot, as you know. and continue to be excited, really excited about the many opportunities that we see ahead. We are working diligently with our teams and partners to execute our strategies and bringing value to our stakeholders I also want to thank and express my thanks to all the Mulek team, the Muellers, also to our partners, investors, the analysts, of course, very grateful for that. for your continued support and helping us to spread the word, to fully explain the Woollex technology and the opportunity ahead. So thank you for that. So thanks again for joining us today. I'm really looking forward to updating you in the next quarter. So as I always say, the best is yet to come. Thank you. Have a good day.
spk01: This concludes MULEX Business Update Conference Call.
Disclaimer